Kin­tor Phar­ma­ceu­ti­cals com­pletes $240 mil­lion IPO; WuXi Bi­o­log­ics is open­ing a Boston plant

→ A Chi­na-based can­cer drug de­vel­op­er, look­ing to pip J&J and Pfiz­er in cas­tra­tion-re­sis­tant prostate can­cer, has com­plet­ed a $240 mil­lion IPO on the Hong Kong Stock Ex­change, mark­ing the fifth over­sub­scribed IPO on the HKEX since De­cem­ber, the South Chi­na Morn­ing Post re­port­ed. Jiang­su-based Kin­tor Phar­ma­ceu­ti­cals‘ lead drug, prox­a­lu­tamide, is an an­dro­gen re­cep­tor an­tag­o­nist now in Phase III tri­als in Chi­na and Phase II in the Unit­ed States.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER